Comments
Loading...
Latest Navidea Biopharmaceutical Stock News | OTC:NAVB | Benzinga
Get the latest news on Navidea Biopharmaceutical stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Navidea Biopharmaceutical performance
Categories: All
Friday, October 06, 2023
Thursday, October 05, 2023
Tuesday, September 26, 2023
Tuesday, September 19, 2023
Thursday, September 14, 2023
Wednesday, September 13, 2023
Thursday, August 17, 2023
Wednesday, August 16, 2023
Monday, July 31, 2023
- Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
- Why Navidea Biopharmaceuticals Shares Are Nosediving
- Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
- Navidea Biopharmaceuticals shares are trading...
- Navidea Biopharmaceuticals Received Written N...
Friday, July 28, 2023
Thursday, July 27, 2023
Friday, June 30, 2023
Thursday, June 29, 2023
Thursday, June 22, 2023
Wednesday, June 21, 2023
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Advanced Health Intelligence Shares Are Trading Higher By 111%; Here Are 20 Stocks Moving Premarket
Friday, June 16, 2023
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Navidea Biopharmaceuticals, Inc. Receives $7....
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Why Squarespace Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Navidea Biopharmaceuticals Shares Halted, New...
Thursday, June 08, 2023
Wednesday, June 07, 2023
Wednesday, May 24, 2023
- Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"
- Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session